Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

• Main Authors: Ferrufino CP (Author), Munakata J (Author), Wei W (Author), Proudfoot C (Author), Kuznik A (Author), Boklage SH (Author), Chen C (Author)
• Format: Book
• Published: Dove Medical Press, 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA Objective: To estimate the 5-year budge...